Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...
The stock experienced a severe reaction following the preliminary data announcement from cohort A of the Ascend trial, indicating potential market misinterpretation. Lisata Therapeutics Inc ...
Lisata Therapeutics (NASDAQ ... Citing early data from Cohort A of its ongoing ASCEND study, which is designed to evaluate certepetide with standard-of-care chemotherapy in mPDAC, LSTA said ...
Lisata Therapeutics Inc (LSTA) advances its pipeline with promising trial results for certepatide, despite facing financial ...